BofA lowered the firm’s price target on BioMarin to $130 from $150 and keeps a Buy rating on the shares following a Q4 report that the firm says was in-line with expectations. The firm still views Roctavian’s clinical profile as “impressive,” but given commercial hurdles both in the U.S. and EU, it has lowered its 2024-2026 forecasts, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
- BMRN Earnings this Week: How Will it Perform?
- Elliott Management bought BioMarin and Etsy during Q4, exited Arm
- BioMarin to present positive data on Roctavian durability at EAHAD Congress
- BioMarin reports Jeffrey Ajer to step down as Chief Commercial Officer
